1. Home
  2. BCPC vs IONS Comparison

BCPC vs IONS Comparison

Compare BCPC & IONS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BCPC
  • IONS
  • Stock Information
  • Founded
  • BCPC 1967
  • IONS 1989
  • Country
  • BCPC United States
  • IONS United States
  • Employees
  • BCPC N/A
  • IONS N/A
  • Industry
  • BCPC Major Chemicals
  • IONS Biotechnology: Pharmaceutical Preparations
  • Sector
  • BCPC Industrials
  • IONS Health Care
  • Exchange
  • BCPC Nasdaq
  • IONS Nasdaq
  • Market Cap
  • BCPC 5.3B
  • IONS 4.6B
  • IPO Year
  • BCPC N/A
  • IONS 1991
  • Fundamental
  • Price
  • BCPC $161.50
  • IONS $28.40
  • Analyst Decision
  • BCPC Strong Buy
  • IONS Buy
  • Analyst Count
  • BCPC 1
  • IONS 18
  • Target Price
  • BCPC $190.00
  • IONS $57.00
  • AVG Volume (30 Days)
  • BCPC 231.1K
  • IONS 2.0M
  • Earning Date
  • BCPC 04-24-2025
  • IONS 04-30-2025
  • Dividend Yield
  • BCPC 0.54%
  • IONS N/A
  • EPS Growth
  • BCPC 17.31
  • IONS N/A
  • EPS
  • BCPC 3.93
  • IONS N/A
  • Revenue
  • BCPC $953,684,000.00
  • IONS $705,138,000.00
  • Revenue This Year
  • BCPC $8.63
  • IONS N/A
  • Revenue Next Year
  • BCPC $8.59
  • IONS $25.80
  • P/E Ratio
  • BCPC $41.25
  • IONS N/A
  • Revenue Growth
  • BCPC 3.39
  • IONS N/A
  • 52 Week Low
  • BCPC $137.69
  • IONS $23.95
  • 52 Week High
  • BCPC $186.03
  • IONS $52.34
  • Technical
  • Relative Strength Index (RSI)
  • BCPC 48.54
  • IONS 44.54
  • Support Level
  • BCPC $159.89
  • IONS $27.57
  • Resistance Level
  • BCPC $164.86
  • IONS $29.04
  • Average True Range (ATR)
  • BCPC 5.92
  • IONS 1.79
  • MACD
  • BCPC 0.40
  • IONS 0.12
  • Stochastic Oscillator
  • BCPC 71.53
  • IONS 68.15

About BCPC Balchem Corporation

Balchem Corp is engaged in the development, manufacture, and marketing of specialty performance ingredients and products for various industries. The company's reportable segments are; Human Nutrition and Health, which generates maximum revenue, and provides human-grade choline nutrients and mineral amino acid chelated products through this segment for nutrition and health applications; Animal Nutrition and Health, which provides nutritional products derived from its microencapsulation and chelation technologies in addition to the essential nutrient choline chloride; and the Specialty Products segment includes re-packaging and distributing several performance gases and chemicals. Geographically, the company derives its key revenue from the United States and the rest from foreign countries.

About IONS Ionis Pharmaceuticals Inc.

Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis received FDA approval in 2024 for Tryngolza for a rare high-triglyceride syndrome, marking its first independent launch.

Share on Social Networks: